QBiotics and Unicancer France sign letter of intent to collaborate on a clinical Phase II Trial, targeting breast cancer recurrence

BRISBANE, 6 March 2026

QBiotics Group Limited (QBiotics) is pleased to announce that it has signed a letter of intent (LOI) to establish a collaborative partnership with Unicancer - the only federation of French hospitals which is 100% dedicated to the fight against cancer. Under the terms of the LOI, the parties intend to negotiate a definitive collaboration agreement to clinically investigate intratumoural tigilanol tiglate for loco-regional and superficial breast cancer recurrences, under an investigator initiated, 50 patients, Phase II multi-centre, open label, single-arm clinical trial.

QBiotics has been working with French world-renowned oncologists, including Professor Aurélien Marabelle, senior oncologist and investigator within the Drug Development Department of Gustave Roussy Cancer Centre Paris, to build clinical experience with tigilanol tiglate through the Compassionate Use Scheme, including for patients with breast cancer. This programme has enabled selected patients in France to receive treatment with tigilanol tiglate, adding further real-world experience, outside of QBiotics’ Phase II development work in Soft Tissue Sarcomas and Head and Neck Cancer.

The decision to formalise this collaboration reflects the encouraging clinical observations and growing body of experience with tigilanol tiglate generated through this work in France.

Interim CEO and Managing Director for QBiotics, Ebru Davidson commented, “Unicancer is recognised as one of Europe’s most respected academic oncology research organisations, with a nationally integrated network conducting more than 740 active clinical trials and playing a central role in advancing cancer innovation across France. Partnering with a federation of such scientific leadership represents an exceptional opportunity for QBiotics.

Through the proposed investigator‑led Phase II programme, we would have the potential to broaden the clinical footprint of tigilanol tiglate and further explore its promise as a novel intratumoural therapy for patients facing superficial breast cancer recurrences- an area where new treatment options are urgently needed. We are excited by what this collaboration may deliver for patients, clinicians, and the future development of our lead oncology candidate. We are now working closely with Unicancer toward finalising a definitive collaboration agreement as the next step in progressing programme.”
 

—ends—
 

FURTHER INFORMATION
EBRU DAVIDSON, INTERIM CEO AND MANAGING DIRECTOR
communications@qbiotics.com

or

MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774

 
NOTES FOR EDITORS

ABOUT QBIOTICS

QBiotics Group Limited (QBiotics) is an Australian public unlisted biotechnology company, advancing two clinical-stage, differentiated, small molecule programmes derived from our epoxytigliane platform.

QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, is demonstrating strong efficacy and safety in human clinical Phase II studies. In a Phase II soft tissue sarcoma study the drug delivered an injected tumour Objective Response Rate (ORR) of 80%, with no serious Adverse Events, and translational research validating immunological responses. A Phase II study in head & neck cancer is soon to be reported and impressive safety and efficacy outcomes have been achieved in a range of other tumour types under Compassionate Use. No Maximum Tolerated Dose (MTD) was declared in a Phase I/IIa safety study and efficacy reported for nine different tumour types.

QBiotics’ second programme is a topically applied regenerative wound therapy EBC-1013 that accelerates wound infill and closure, minimises scarring, and provides local antimicrobial activity. This drug candidate has demonstrated impressive safety and efficacy against chronic and acute wounds and burns in veterinary studies. It is currently in a human clinical Phase I/IIa study treating Venous Leg Ulcers.

Patent coverage for tigilanol tiglate and EBC-1013 is broad and Chemistry, Manufacturing and Controls (CMC) is mature, with commercial supply of the drug secured for both programmes.

QBiotics employs a capital-efficient model that integrates its EcoLogic™ discovery technology with phenotypic screening and early validation in veterinary disease models. This approach enables rapid identification of biologically active molecules, early demonstration of efficacy and safety in complex disease settings, and meaningful de-risking prior to human clinical development. Product development is led by an experienced team and complimented by internationally recognised Key Opinion Leaders on our Clinical and Scientific Advisory Boards, who bring deep expertise in oncology, wound healing, antimicrobials, and translational drug development.

QBiotics’ business strategy is to advance therapeutic programmes with the potential to address multiple high-value indications through to Phase II proof-of-concept in human clinical studies, and then pursue strategic partnering to accelerate late-stage development and commercialisation.

For more, head to: QBiotics.com or LinkedIn 

ABOUT UNICANCER

Unicancer is the only French hospital network entirely dedicated to the fight against cancer and the only national hospital federation specializing in oncology. It brings together the 18 French Cancer Centers (CLCC) – private non-profit institutions – as well as two affiliated members. A major player in research, Unicancer lead more than 730 active clinical trials around the word, and is recognised as the leading academic promoter of clinical trials in oncology in Europe. In addition, there are more than 600 trials promoted by the CLCCs. A pioneer in the use of health data, since 2014 Unicancer has launched five real-life data programs through its data and partnerships department, including ESME (109,000 patients), CANTO (+13,000 patients), and OncoDataHub (ODH) (+60,000 patients). Each year, more than 600,000 patients benefit from the latest scientific, therapeutic, and organizational advances in oncology, supported by an agile model combining excellence, humanism, solidarity, and innovation. www.unicancer.fr

For more, please visit: https://www.unicancer.fr/en/